Related Experiment Video

Updated: Apr 14, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications

Shuju Wu1, Lijie Yu2

  • 1School of Life Science and Technology, Harbin Normal University, Harbin, 150025, People's Republic of China. shuju1965@gmail.com.

Cytotechnology
|April 23, 2015
PubMed

Insights

Targeting the ubiquitin-proteasome system (UPS) offers cancer therapy potential. MLN4924, a novel inhibitor of NEDD8 activating enzyme (NAE), shows promise in treating malignancies by disrupting Cullin RING ligase activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The ubiquitin-proteasome system (UPS) is a crucial regulator of cellular protein degradation.
  • Bortezomib's success in multiple myeloma highlights the UPS as a therapeutic target, but side effects are a concern.
  • Cullin RING ligases (CRLs) mediate ubiquitination of a significant portion of cellular proteins targeted by the UPS.

Purpose of the Study:

  • To review the role of NEDDylation in controlling CRL activity.
  • To summarize the anti-tumor mechanisms of MLN4924, a NEDD8 activating enzyme (NAE) inhibitor.
  • To discuss the therapeutic potential of targeting the NEDDylation pathway in human malignancies.

Main Methods:

  • Review of recent scientific literature on NEDDylation, CRLs, and MLN4924.
  • Analysis of molecular mechanisms underlying MLN4924's anti-cancer effects.
  • Summary of clinical trial data for MLN4924 in various cancers.

Main Results:

  • NEDDylation is a key regulatory step controlling CRL activity.
  • MLN4924 effectively inhibits NAE, leading to decreased CRL activity.
  • MLN4924 demonstrates potent anti-tumor activity in preclinical and early clinical studies.

Conclusions:

  • Targeting the NEDDylation pathway with inhibitors like MLN4924 represents a promising new strategy for cancer therapy.
  • MLN4924's specific mechanism offers a potential alternative to broader proteasome inhibitors, possibly with a different side effect profile.
  • Further clinical development of MLN4924 is warranted for various human malignancies.
Keywords:
DNA damageMLN4924NEDD8NEDDylationUbiquitinmTOR

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K